Overview

Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas

Status:
Withdrawn

Trial end date:
2018-04-18

Target enrollment:
0

Participant gender:
All

Summary

Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Tainan Municipal Hospital

Treatments:

Antiviral Agents
Asunaprevir
Interferons

Criteria

Inclusion Criteria:

1. Men and women

2. 18 to 70 years of age

3. Who had chronic HCV genotype 1b infection

4. An HCV RNA level of 105 IU per milliliter or higher

5. Being diagnosed to be low grade B cell non-Hodgkin lymphoma

Exclusion Criteria:

1. Patients with hepatitis B virus infection,

2. Other liver diseases

3. HIV infection,

4. Pre-existing HCV variants in the NS5A domain included Q30R, L31 M/V, and Y93C/N

5. Evidence of cirrhosis, as documented by means of either liver biopsy or assessment of
imaging results.